Improving Adolescent Human Papillomavirus Vaccination Rates Through Provider Education

Tierra Schulz

Arizona State University

Abstract

Human papillomavirus (HPV) is a prevalent sexually transmitted infection that affects many adolescents and adults worldwide. The consequences of contracting HPV have proven to be devastating, potentially leading to a variety of life-threatening genitourinary and oral cancers. As such, prevention via vaccination is critical. HPV vaccination is recommended for all adolescents beginning at 11 years of age. Although the immunization has proven to be safe and effective, HPV vaccination rates are substantially below target goals worldwide. A literature review of evidence from the last five years was conducted to examine barriers and facilitators to HPV vaccine uptake. The most commonly cited barriers to vaccination included lack of knowledge about the vaccine and inadequate provider recommendation. Current evidence regarding interventions to increase HPV vaccine uptake reveal that best practices are multi-factorial and should include a combination of provider education and recommendation training. These findings led to the proposal of an evidence-based intervention aimed to increase adolescent HPV vaccination rates. A one-hour educational program was conducted at a local pediatric primary care facility. Five healthcare providers participated in the program, which consisted of a PowerPoint presentation outlining the benefits of HPV vaccination and use of an interactive application from the CDC. The app taught participants how to offer a strong recommendation for the vaccine through active participation. Pre and posttests were administered to determine the providers' intent to vaccinate and vaccination rates were monitored. Analysis of the data collected revealed a statistically significant rise in vaccination rates. These results reveal that provider education can improve recommendation techniques and therefore increase vaccine coverage. Further research is needed to see if one-time education is sustainable.

Keywords: Adolescents, HPV, human papillomavirus, provider education, vaccination

Improving Adolescent HPV Vaccination Rates

Vaccination against human papillomavirus (HPV) is currently recommended by the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) for both males and females aged 11-26 years (CDC, 2018). Despite numerous clinical trials that led the Food and Drug Administration and CDC to deem the vaccine both safe and effective at preventing genitourinary cancers, HPV vaccination rates are still remarkably lower than all other required adolescent vaccinations. Failing to immunize against HPV as an adolescent can potentially lead to lifelong consequences. A joint statement released by 69 of the National Cancer Institute (NCI) centers refers to low HPV vaccination rates as a serious public health threat (National Institute of Health, 2016).

Background and Significance

Human papillomavirus refers to more than 200 different strains of related viruses that can be spread through sexual contact. It is the most common sexually transmitted infection, affecting more than 79 million Americans (CDC, 2018). While low risk strains of HPV can lead to genital warts, high risk HPV can lead to cervical, anal, oral, penile, or vulvar cancers (NIH, 2018). The HPV vaccine protects against nine different strains, seven of which can potentially lead to cancer (CDC, 2018). There are 33,000 new cases of cervical cancer diagnosed in the United States annually, leading to 4,000 deaths each year. Vaccinating against HPV can prevent 90% of these cases (CDC, 2018).

The HPV vaccine is currently recommended by the CDC and ACIP for all adolescents beginning at 11 years of age, yet in 2017 only 66% of adolescents initiated the vaccine and 49% were up to date, falling significantly short of the *Healthy People 2020* goal of 80% (CDC, 2018). After introduction of the HPV vaccine, HPV related cancers and genital warts decreased by 71%

in adolescents (CDC, 2018). Despite the proven efficacy, only 29.5% of girls and 24.9% of boys complete the series by age 13 (Vollrath, Thul, & Holcombe, 2018).

Internal Evidence

The Director of Professional Practice and the Chief Clinical Services at a local pediatric primary care facility report an office HPV vaccination rate of 13-18%, significantly below state and national levels. A poll of the providers at this location indicates that many do not routinely recommend the vaccine and often offer delayed dosing.

Purpose and Rationale

In 2017, 44% of parents made the decision to not vaccinate their child against HPV (CDC, 2018). This decision may lead to deleterious consequences for them as they grow into adulthood. The purpose of this evidence-based project is to improve provider knowledge regarding the HPV vaccine and intent to vaccinate. These practice changes are anticipated to increase HPV vaccine uptake in adolescents between ages 11-18 years. The inquiry into this clinical problem leads to the PICO question: In pediatric healthcare providers, does an educational class on the HPV vaccine and recommendation techniques versus no educational offering affect overall HPV knowledge and vaccination rates?

Evidence Synthesis

Search Strategy

An extensive review of current literature was performed to answer the PICO question. The databases searched included PubMed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), and Cochrane Library. The databases were searched using a combination of the following terms: adolescents, teenagers, caregivers, parents, health care providers, HPV vaccination, HPV rates, human papillomavirus, education, and recommendation. Boolean and MeSH terms were added to broaden the search. Initial searches yielded 116 results in PubMed, 84 in CINAHL, and 55 in Cochrane Library. Filters were then applied to include only English language, peer reviewed articles published between 2013 and 2019 with an age limit of 18 years old. This final search yielded 60 results in PubMed, 52 in CINAHL, and 46 in Cochrane Library.

The abstracts of each article were reviewed for quality and relevance. Inclusion criterion included educational interventions aimed at increasing HPV vaccination rates in adolescents. Exclusion criterion included participants older than 18 years old receiving the vaccine and articles published prior to 2013. After critical appraisal of each article, 14 have been chosen based on merit and relevance to the PICO question to be included in the literature review.

Critical Appraisal

Fourteen studies were chosen to be included in the literature review based on quality, relevance and merit determined by Melnyk and Fineout-Overholt's (2005) rapid critical appraisal. Of the 14 studies selected, 10 were randomized controlled trials, which are considered to be a high-level of evidence. The remaining four studies used surveys and levels of evidence ranged from III to VI (Appendix A). Funding was disclosed for all but two of the studies, with only two being funded by a pharmaceutical company, which could lead to a potential sponsorship bias. Each of the 14 studies took place in an outpatient, primary care setting within the United States and had adequate samples of adolescents aged 9-18 years old. Heterogeneity was observed in the demographics of the sample, with an equal volume of males and females and a wide variety of ethnicities represented (Appendix B).

Intervention methods varied widely amongst each of the studies. Single component and multi-component methods were evaluated, including provider communication classes, web-based videos for parents, and printed fact sheets. Due to the variability, it was difficult to assess which

of these methods would be most beneficial. Despite heterogeneity of the interventions, there was a commonality amongst all. Each of the studies provided education to parents or providers regarding the risks of HPV, the benefits of HPV vaccination, and why it is important to vaccinate at a young age.

While secondary outcomes such as provider comfort level and parent perception were measured in three studies, the main outcome assessed in all but two of the studies was a change in HPV vaccination rates. The measurement tools were homogeneous amongst studies due to the fact that there are limited methods to track HPV vaccination rates. Methods included an online registry, electronic medical records, and self-report through surveys (Appendix A).

Foundation of Evidence

After an exhaustive review of the literature was performed, parental hesitancy was identified in numerous studies as a barrier to HPV vaccination. The greatest report of parental hesitancy (17%) stems from the lack of a recommendation from a medical provider (Holman et al., 2014). Eleven of the fourteen studies examined in this review cite the lack of a strong provider recommendation as the leading cause for parents not accepting the HPV vaccine. Parents frequently reported that their child's medical provider did not recommend the vaccine, with only 58.8% of girls receiving a recommendation and 14.2% of boys (Rahman, Laz, McGrath, & Berenson, 2014). Overall, the HPV vaccine was only strongly recommended by a provider 39% of the time compared to other adolescent vaccines, which were strongly recommended 59% of the time. Receiving a strong recommendation from a provider makes an adolescent five to seven times more likely to receive the vaccine than if receiving no recommendation (Dempsey & O'Leary, 2018; Dempsey et al., 2015; Ylitalo, Lee, & Mehta, 2013). Findings indicate that provider recommendation increases uptake of the HPV vaccine by

creating a positive parental perception of the immunization. That positive attitude is diminished, however, if the vaccine is presented as optional (Dempsey et al., 2015; Underwood et al., 2016).

In a recent survey conducted by Warner et al. (2017), pediatricians had the lowest proportion of knowledge (26.7%) regarding the HPV vaccine out of all specialty providers. Providers are less likely to recommend the HPV immunization if they have little knowledge about the vaccine (Holman et al., 2014). Provider based interventions should aim to increase knowledge and therefore the strength of the recommendation to patients. After one hour of provider education, which entails general HPV knowledge and the correct structure of a strong recommendation, providers are significantly more likely to recommend the HPV vaccine and administer it at minimum dosing intervals (Volrath, Thul, & Holcombe, 2018). A study by Dempsey and O'Leary (2018) found that a strong recommendation results in 89% HPV vaccine acceptance rate, whereas a weak recommendation results in a 71% acceptance rate. Learning to frame a strong recommendation is a mainstay of provider education.

This literature review demonstrates that educational interventions aimed at providers or parents could lead to an increase in overall HPV vaccination rates. The most common intervention analyzed was an HPV education and communication course for providers, which attempted to nullify each of the top parent and provider barriers to vaccination. Findings from this literature review report that provider trainings not only increase HPV vaccination rates, but also significantly improve both parent and provider perceptions of the vaccine.

Conceptual Framework and EBP Model

The conceptual framework used to guide this project was the Health Belief Model (HBM), which attempts to predict an individual's health behaviors by focusing on their attitudes and beliefs towards an illness (Donadiki et al., 2014). In this model, an individual will take a

health related action, such as vaccination, only if they feel as though the illness is a personal threat to them and whether the suggested health behavior is safe, beneficial and effective (Appendix C). Studies indicate that HPV vaccination rates are low due to both provider beliefs that there is a low risk of adolescents contracting HPV and doubts regarding the safety of the vaccine. If providers have doubts or concerns regarding the vaccine, they are less likely to recommend it to their patients. An intervention designed to educate providers about the severity of contracting HPV, the benefits of the vaccine to society, and the safety profile should foster positive attitudes and beliefs towards the vaccine, leading to a strong recommendation. Findings from several studies indicate that provider recommendation increases uptake of the HPV vaccine by creating a positive parental perception of the immunization (Dempsey et al., 2015). That positive parental perception, according to the HBM, will then lead to them taking the health related action of vaccination.

In addition to the HBM, Rosswurm and Larrabee's (1999) model was chosen to guide individuals systematically through the process of developing and implementing an evidencebased practice change (Appendix D). The process begins with assessing the need for change. State and national averages for HPV vaccination rates are markedly below target goals, indicating improvements need to be made in the HPV vaccination process. Next, potential interventions must be identified and recent evidence synthesized to support the intervention based on feasibility, benefits, and risk. Provider education and communication training has been supported by recent evidence to be a potential low cost intervention that significantly improves vaccination rates. Once the intervention is identified, the practice change can then be designed, where outcomes and resources are identified and the practice change is implemented and evaluated. If positive outcomes are achieved, the practice change can be integrated and maintained in practice (Appendix D) (Rosswurm & Larrabee, 1999).

Methods

Ethical Considerations

University Institutional Review Board (IRB) approval was obtained prior to project implementation. Physical data (surveys) were de-identified by assigning unique coded numbers to individuals and were stored in a locked file cabinet. Electronic data was also de-identified and stored on an encrypted, password-protected computer. All information will be deleted at the completion of the project.

Population and Setting

Five healthcare providers (nurse practitioners and physicians) were eligible to participate in this evidence-based project. Inclusion criteria included being a healthcare provider employed by the project site and having an interaction with adolescents who were eligible for the HPV vaccine. Participants were excluded if they did not provide direct care to patients or if they did not attend the staff meeting where the intervention was presented. The project was conducted in a pediatric primary care facility located in Mesa, Arizona. The clinic provides services such as well child exams, sick visits, and immunization encounters for children from birth to age 18 years.

Procedure

The Director of Professional Practice for the organization was contacted regarding potential participation in the project. Upon agreement of participation, the project director contacted the clinic manager to arrange a date and time for the intervention that was convenient for potential participants. In July of 2019, the project site champion identified eligible participants. The project director distributed a recruitment letter to the potential participants prior to the start of the intervention. The recruitment letter described the evidence-based project and also served as the consent form. By choosing to stay and take part in the intervention, individuals consented to be an active participant in the project. An eight-point questionnaire along with a demographic data form was then distributed to eligible participants. Each participant had 10 minutes to complete the questionnaire. After all questionnaires were completed, a one-hour educational course regarding HPV and the HPV vaccine commenced. Led by the project director, 30 minutes were dedicated to providing a PowerPoint presentation regarding the risks of HPV, the benefits of the vaccine, and tips for providing a strong, assumptive recommendation. During the final 30 minutes, an interactive video from the CDC and American Academy of Pediatrics was shown. The web-based app (Same Day, Same Way) is an interactive video about how to give a strong recommendation for the HPV vaccine. The app simulated typical parentprovider interactions that take place during adolescent visits and allowed the providers to choose how they would recommend the vaccine and answer frequently asked questions. Based on their responses, the virtual patient and parent would make a decision to either accept or decline the vaccine. Feedback was then given to participants about how to better frame their recommendations. Immediately following the hour-long educational intervention, a post-survey was distributed for participants to complete. A final post-survey was hand-delivered to the participants three months post intervention.

Data Collection and Outcome Measures

The primary outcome measured was overall HPV vaccination rates, while secondary outcomes included provider knowledge and intent to vaccinate. The Clinical Services Director pulled vaccination rates monthly from the electronic medical record. Administration rates were pulled both collectively for the clinic and individually by provider. Intent to vaccinate was measured using a modified *Determinants of Intent to Vaccinate (DIVA)* survey. This 56-item questionnaire is intended to assess provider commitment to vaccination and knowledge regarding the vaccine. The questions are grouped into six different domains: (a) 'properties of the vaccine', (b) 'disease characteristics/benefits', (c) 'information about the vaccine', (d) 'practical aspects', (e) 'adaptation', and (f)'primary care provider's experience' (Martinez et al., 2016). Prescribing providers are asked questions within each of these domains and must choose from four possible responses on a scale between 1= "totally disagree", 2= "somewhat disagree", 3= "somewhat agree" and 4= "totally agree". Of the 56 questions in the original questionnaire, eight were chosen for the modified version due to time constraints of the participants. The *DIVA* tool was found to be a valid and reliable instrument to assess provider intent to vaccinate, with a Cronbach's alpha of 0.85. A Delphi panel also concluded that the *DIVA* questionnaire could be utilized as a stand-alone tool in assessing provider commitment to vaccinate against HPV, finding good internal consistency and reliability (Martinez et al., 2016).

Budget and Funding

The intervention for this project was cost-effective with minimal out-of-pocket expenses. The majority of the budget plan (Appendix E) was allocated to printed copies of the pre and post surveys, which are not necessary for project implementation. There was also the potential for the associated cost of paying the providers' salary or loss of patient revenue if the education was provided at any time other than the lunch hour. This project was implemented during the lunch hour, so while there was no loss of revenue, a meal was provided. There were no grants awarded for this project. The student provided all funding.

Results

Five providers returned completed surveys to the project director (N=5). Answers provided were converted to a Likert scale and given a score. A Wilcoxon Signed Rank Test was conducted to compare the average scores for provider intent to vaccinate pre-intervention versus post-intervention. Scores could not be analyzed due to constant variables, indicating there was no difference in provider intent to vaccinate pre-intervention compared to post-intervention.

Vaccination rates for the clinic, and per provider, were pulled for five months prior to intervention and five months post intervention. A repeated measures of analysis of variance (ANOVA) was conducted to determine if there were any significant differences in individual provider vaccination rates between the months before the intervention and the months after. The results were examined based on an alpha of 0.05. The main effect for the within-subjects factor was not significant (F(4, 16) = 1.96, p = .200), indicating that vaccination rates pre-intervention and post-intervention were similar. A two proportions z-test was also conducted to determine whether there was a significant difference between the proportion of total eligible adolescents (N=2,096) who accepted the vaccine pre-intervention and the proportion of total eligible adolescents (N=2,428) who accepted the vaccine post-intervention. The result of the two proportions z-test was statistically significant based on an alpha of 0.05 (z = -5.12, p = <.001) indicating that the proportion of children accepting the vaccine pre-intervention was significantly lower than children accepting the vaccine post-intervention. These results are consistent with the literature in that increasing provider knowledge and the strength of their recommendation leads to increased vaccine uptake.

Potential Impact

Implementing a provider-based educational training on HPV will lead to practitioners having increased knowledge regarding the benefits of the vaccine and will increase their comfort

and confidence in delivering a stronger and more timely recommendation to parents. This recommendation will in turn empower parents with knowledge of the importance of vaccinating, leading to increased vaccine uptake. Significantly improving HPV vaccination rates will ultimately lead to a decreased incidence of HPV related genitourinary cancers, thus creating better health outcomes for our population.

Project Sustainability

The one-hour educational course provided during this evidence-based project can be easily replicated at other pediatric primary care facilities throughout the organization. The materials used were electronic and tailored to train any type of pediatric provider. As such, the course could be effortlessly sent to and implemented at other pediatric facilities. The site would need an individual who is trained in using the course materials to facilitate the class as well as time allotted to provide the education. There would be no additional cost to the organization.

Discussion

Summary and Conclusions

Low HPV vaccination rates in Arizona and the United States indicate the need for an evidence-based intervention aimed at increasing immunization uptake. This project demonstrates that provider education intended to strengthen recommendation techniques can successfully improve overall vaccination rates. While survey results of this project indicate that provider intent to vaccinate did not improve, this is likely due to the fact that individual intent was already at peak potential pre-intervention. This conclusion was reached as providers had high preintervention scores with no room for improvement post-intervention. This suggests that providers were already intending to vaccinate all adolescents, yet their current practice was not sufficient to promote vaccination. By implementing a provider education course, techniques were given on how to improve vaccine recommendations and therefore uptake.

Vaccination rates did improve post-intervention for each individual provider. Though this is clinically significant, given the small sample size of five providers, rates were not statistically significant. Additional data was also analyzed, using a larger sample size of total adolescents eligible for the vaccine. The proportion of eligible adolescents that accepted the vaccine post-intervention was significantly higher than the proportion of eligible adolescents that accepted the vaccine the vaccine prior to the intervention. These results are consistent with suggestions from the literature in that increasing provider knowledge and the strength of their recommendation leads to increased vaccine uptake.

Limitations and Barriers

There were several limitations and barriers noted throughout this project. The barriers that were encountered included reluctance from two providers to participate and time constraints. There were significant challenges in pulling vaccination rates for the office without including the rates for the non-participating providers. This initially led to the possibility of skewed data and falsely low vaccination rates. However, upon further evaluation, an alternative method for extracting vaccination rates was developed to alleviate that potential issue. The participating providers also voiced concern that they had limited time to properly discuss the HPV vaccine given their short ten-minute appointment windows. Furthermore, an additional limitation of the project was the inability of the electronic medical record to separate administration of the first dose versus subsequent doses of the HPV vaccine. Separating this data would have allowed for the opportunity to determine if series initiation or series completion was of greater concern for the facility.

Recommendations

Office vaccination rates began to decline two months after the education was provided. This would seemingly indicate that continuing education is needed to reinforce recommendation techniques and the importance of HPV vaccination. It is recommended that similar education be provided to all medical staff in direct contact with adolescent patients on a quarterly basis to continually improve vaccine uptake.

The educational course provided during this project was implemented just prior to the start of school, which is typically when a large influx of patients are seen by their primary care provider for back-to-school needs. Given the decline of vaccination rates over time post-intervention, and the timing of the delivery of the intervention, future studies are needed to determine if provider education courses about HPV vaccination are equally successful in improving vaccination rates at different time periods throughout the year.

Conclusion

Human papillomavirus vaccination rates in adolescents are significantly below target goals, creating missed opportunities for reducing cancer cases. The lack of a recommendation from a medical provider is a driving factor that limits vaccination. Attempting to improve HPV vaccination rates amongst adolescents is a daunting task, especially considering it is a worldwide issue. Utilizing knowledge gained from the literature, an evidence-based intervention was developed in an effort to improve vaccine uptake. Through implementation of a provider education course in which techniques were given on how to provide a strong recommendation, HPV vaccination rates improved significantly. These findings indicate that educational interventions, system changes, and improved provider recommendation could lead to an increase in overall HPV vaccination rates and therefore a decrease in HPV related cancer deaths.

References

- Beavis, A., Krakow, M., Levinson, K., & Rositch, A. F. (2018). Reasons for lack of HPV vaccine initiation in NIS-teen over time: Shifting the focus from gender and sexuality to necessity and safety. *Journal of Adolescent Health*, 63(5), 652–656. Doi: 10.1016/j.jadohealth.2018.06.024
- Brewer, N., Hall, M., Malo, T., Gilkey, M., Quinn, B., & Lathren, C. (2017). Announcements versus conversations to improve HPV vaccination coverage: A randomized trial. *Pediatrics*, 139(1), e20161764. Doi: 10.1542/peds.2016-1764
- Centers for Disease Control and Prevention. (2018). HPV vaccination coverage. Retrieved from: https://www.cdc.gov/hpv/hcp/vacc
 - coverage/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fhpv%2Fhc p%2Fvacc-coverage.html
- Dempsey, A. F., Pyrzanowski, J., Campagna, E. J., Lockhart, S., & O'Leary, S. T. (2019). Parent report of provider HPV vaccine communication strategies used during a randomized, controlled trial of a provider communication intervention. *Vaccine*, *37*(10), 1307–1312.
 Doi: 10.1016/j.vaccine.2019.01.051
- Dempsey, A., Pyrznawoski, J., Lockhart, S., Barnard, J., Campagna, E., Garrett, K., ... O'Leary,
 S. (2019). Effect of a health care professional communication training intervention on adolescent human papillomavirus vaccination: A cluster randomized clinical trial. *JAMA Pediatrics*, *172*(5), e180016. Doi: 10.1001/jamapediatrics.2018.0016
- Dempsey, A. F., & O'Leary, S. T. (2018). Human papillomavirus vaccination: Narrative review of studies on how providers' vaccine communication affects attitudes and uptake. *Academic Pediatrics*, 18(2), S23–S27. Doi: 10.1016/j.acap.2017.09.001

Dempsey, A. F., Pyrzanowski, J., Lockhart, S., Campagna, E., Barnard, J., & O'Leary, S. T.
(2016). Parents' perceptions of provider communication regarding adolescent vaccines. *Human Vaccines & Immunotherapeutics*, *12*(6), 1469–1475. Doi:
10.1080/21645515.2016.1147636

- Dixon, B. E., Zimet, G. D., Xiao, S., Tu, W., Lindsay, B., Church, A., & Downs, S. M. (2019). An educational intervention to improve HPV vaccination: A cluster randomized trial. *Pediatrics*, 143(1).Doi: 10.1542/peds.2018-1457
- Donadiki, E. M., Jiménez-García, R., Hernández-Barrera, V., Sourtzi, P., Carrasco-Garrido, P.,
 López de Andrés, A., ... Velonakis, E. G. (2014). Health belief model applied to noncompliance with HPV vaccine among female university students. *Public Health*, *128*(3),
 268–273. Doi: 10.1016/j.puhe.2013.12.004
- Garbutt, J. M., Dodd, S., Walling, E., Lee, A. A., Kulka, K., & Lobb, R. (2018). Barriers and facilitators to HPV vaccination in primary care practices: a mixed methods study using the consolidated framework for implementation research. *BMC Family Practice*, *19*(1), 53. Doi: 10.1186/s12875-018-0750-5
- Gilkey, M. B., Malo, T. L., Shah, P. D., Hall, M. E., & Brewer, N. T. (2015). Quality of physician communication about human papillomavirus vaccine: Findings from a national survey. *Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology*, 24(11), 1673–1679. Doi: 10.1158/1055-9965.EPI-15-0326
- Gilkey, M. B., Moss, J. L., Coyne-Beasley, T., Hall, M. E., Shah, P. D., & Brewer, N. T. (2015).
 Physician communication about adolescent vaccination: How is human papillomavirus vaccine different? *Preventive Medicine*, 77, 181–185. Doi: 10.1016/j.ypmed.2015.05.024

- Holman, D., Benard, V., Roland, K., Watson, M., Liddon, N., & Stokley, S. (2014). Barriers to human papillomavirus vaccination among US adolescents. *JAMA Pediatrics*, *168*(1), 76-82. Doi: 10.1001/jamapediatrics.2013.2752
- Krantz, L., Ollberding, N. J., Beck, A. F., & Carol Burkhardt, M. (2018). Increasing HPV vaccination coverage through provider-based interventions. *Clinical Pediatrics*, 57(3), 319–326. Doi: 10.1177/0009922817722014
- Kumar, M., Boies, E., Sawyer, M., Kennedy, M., Williams, C., & Rhee, K. (2019). A brief provider training video improves comfort with recommending the human papillomavirus vaccine. *Clinical Pediatrics*, 58(1), 17–23. Doi: 10.1177/0009922818805217
- Malo, T. L., Hall, M. E., Brewer, N. T., Lathren, C. R., & Gilkey, M. B. (2018). Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation. *Implementation Science*, *13*(57). Doi: 10.1186/s13012-018-0743-8
- Martinez, L., Fofana, F., Raineri, F., Arnould, P., Benmedjahed, K., Coindard, G...Arnould, B.
 (2016). Scoring and psychometric validation of the "Determinants of Intentions to Vaccinate' (DIVA) questionnaire. BMC Family Practice 17(171). Doi: DOI 10.1186/s12875-016-0539-3
- McLean, H., VanWormer, J., Chow, B., Birchmeier, B., Vickers, E., DeVries, E., ... Belongia,
 E. (2017). Improving human papillomavirus vaccine use in an integrated health system:
 Impact of a provider and staff intervention. *Journal of Adolescent Health*, *61*(2), 252–258. Doi: 10.1016/j.jadohealth.2017.02.019
- National Cancer Institute. (2016). The HPV vaccination crisis. Retrieved from: https://www.cancer.gov/news-events/cancer-currents-blog/2016/hpv-vaccination-rates

- Perkins, R., Zisblatt, L., Legler, A., Trucks, E., Hanchate, A., & Gorin, S. (2015). Effectiveness of a provider-focused intervention to improve HPV vaccination rates in boys and girls. *Vaccine*, 33(9), 1223–1229. Doi: 10.1016/j.vaccine.2014.11.021
- Rahman, M., Laz, T. H., McGrath, C. J., & Berenson, A. B. (2015). Provider recommendation mediates the relationship between parental human papillomavirus (HPV) vaccine awareness and HPV vaccine initiation and completion among 13–17 year old US adolescent children. *Clinical Pediatrics*, *54*(4), 371–375. Doi: 10.1177/0009922814551135
- Rosswurm, M., & Larrabee, J. (1999). A model for change to evidence-based practice. *Imagethe Journal of Nursing Scholarship*, *31*(4), 317–322.
- Sanderson, M., Canedo, J., Khabele, D., Fadden, M., Harris, C., Beard, K., ... Hull, P. (2017). Pragmatic trial of an intervention to increase human papillomavirus vaccination in safetynet clinics. *BMC Public Health*, 17. Doi: 10.1186/s12889-017-4094-1
- Selove, R., Foster, M., Mack, R., Sanderson, M., Hull, P. (2017). Using an implementation research framework to identify potential facilitators and barriers of an intervention to increase HPV vaccine uptake. *Journal of Public Health Management and Practice, 23*(3), e1-e9. Doi: 10.1097/PHH.000000000000367
- Sturm, L., Donahue, K., Kasting, M., Kulkarni, A., Brewer, N. T., & Zimet, G. D. (2017).
 Pediatrician-parent conversations about human papillomavirus vaccination: An analysis of audio recordings. *Journal of Adolescent Health*, 61(2), 246–251. Doi: 10.1016/j.jadohealth.2017.02.006
- Underwood, N. L., Gargano, L. M., Jacobs, S., Seib, K., Morfaw, C., Murray, D., ... Sales, J. M. (2016). Influence of sources of information and parental attitudes on human

papillomavirus vaccine uptake among adolescents. *Journal of Pediatric and Adolescent Gynecology*, 29(6), 617–622. Doi: 10.1016/j.jpag.2016.05.003

- Vollrath, K., Thul, S., & Holcombe, J. (2018). Meaningful methods for increasing human papillomavirus vaccination rates: An integrative literature review. *Journal of Pediatric Health Care*, 32(2), 119–132. Doi: 10.1016/j.pedhc.2017.07.005
- Walling, E. B., Benzoni, N., Dornfeld, J., Bhandari, R., Sisk, B. A., Garbutt, J., & Colditz, G.
 (2016). Interventions to improve HPV vaccine uptake: A systematic review. *Pediatrics*, *138*(1), e20153863. Doi: 10.1542/peds.2015-3863
- Warner, E., Ding, Q., Pappas, L., Bodson, J., Fowler, B., Mooney, R.,...Kepka, D. (2017).
 Health care providers' knowledge of HPV vaccination, barriers, and strategies in a state with low HPV vaccine receipt: Mixed-methods study. *JMIR Cancer*, *3*(2). Doi: 10.2196/cancer.7345
- Ylitalo, K. R., Lee, H., & Mehta, N. K. (2013). Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US national immunization survey.
 American Journal of Public Health, 103(1), 164–169. Doi: 10.2105/AJPH.2011.300600

Appendix A

Table 1

Evaluation Table

Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables and	Measurement	Data Analysis	Study Findings	Decision for Use
				Definitions				
Brewer et al.	Inferred	RCT (3 & 6 month	N=30 (clinics)	IV1- 1 hr	Online vax	Power analysis	IV1-	LOE: II
(2017).	Theory of	FU)	n = 10 (CG)	provider	registry		3 month:	
Announcements	Planned		n =10 (IV1)	announcement		ITT	IG difference from	Strengths:
versus	Behavior	Purpose: To	n =10 (IV2)	training			CG- 5.1%	randomized,
conversations to		determine if				Fisher's exact	p=.003	standardized
improve HPV		announcement or	Pt type: Vax	IV2- 1 hr				intervention, low
vaccination		conversation	prescribing	provider		ANOVA	6 month:	attrition, large sample
coverage: A		training lead to	providers	conversation			IG difference from	
randomized		larger increases in		training		Poisson regression	CG- 5.4%	Weaknesses:
trial.		HPV vax coverage	A:				p=.02	unknown providers
			11-12- 31%	DV- Change in				adherence to
Country: USA			13-17- 69%	HPV vax			IV2-	intervention
Funding:				initiation			3 month:	
Pfizer &			Setting: Primary	between baseline			IG difference from	Conclusions: Brief
National Cancer			care clinic	& 6 months post			CG- 2%	provider
Institute			serving 11-				p=.10	announcement
Bias:			12yo's	Definition-				training increases
Sponsorship				announcement-			6 month:	HPV vax rates,
Bias			Exclusions:	1) due for 3 vax			IG difference from	conversation training
			prior QI to	2) HPV middle			CG- 2%	does not
			increase HPV	of vax stated			p=.24	
			vax rates w/i last	3)state you will				Feasibility: Low
				vax				cost and resources

			6 months, <100					
			11-12 yo patients	Conversation-				
				1) introduce 3				
			Attrition: 3%	vax needed				
			(clinic closed)	2)place HPV in				
				middle of list				
				3) discuss health				
				benefits, ask if				
				questions				
Citation	Componenting	Destan /Mathad	Comm lo/Cottin o	Maian	Maaguuana		Standar Findings	Desision for Use
Citation	Conceptual	Design/Method	Sample/Setting	Major Variables and	Measurement	Data Analysis	Study Findings	Decision for Use
	Framework			Variables and				
Domnsov at al	Dracoution	рст	N- 42 122	Definitions	EMD	ITT	DV1.	
(2010) Effect	riecaution-	CSS	N = 43,132 n = 21,802 (CC)	IV: J	EMIK	111		LUE: II Strongther
(2019). Effect		CSS	n=21,092 (CO) n=21,240 (IC)	UDV fact sheet	Online yes	Concretized linear	U . 11 20/	bataroganaity of
	model	Dumpered To	II = 21,240 (IG)	mr v fact sheet,		mixed model	1.1.5%	treatment offects
professional	model	Purpose: 10	D4 4		registry	mixed model	p < .001	treatment effects
communication		determine 11	Pt type:	website, images	C	Tatanant anla	OK = 1.40	analysis, randomized,
training		multimodal	Adolescents 9yo	OI HPV	Surveys	Intercept-only	DUA	large sample size
intervention on		provider	or older	diseases,		model	DV2:	XX7 - 1 11
adolescent		intervention would	presenting for	decision and for		Description	UG: -5.5%	weaknesses: small
Human		increase HPV vax	care	HPV vax, 2.5 nr		Descriptive	IG: -0.9%	geographic area not
Papillomavirus		rates	A:	provider		statistics	OR=1.56	generalizable, long
vaccination.			Median-12.6yo	communication			DIA 52 000/	term FU not assessed
G (110)			S:	training			DV3: 72-90%	
Country: USA			f- 50.3%	DUA CI			used	Conclusion:
Funding: Not			m-49./%	DVI: Change			communication	Substantial and
disclosed			D	over time			techniques (most	sustained increase in
Bias: None			R:	between IG and			frequently used).	HPV vax initiation
			c-54.9%	CG in initiating			91% likely to	after multicomponent
			b-4.5%	HPV series			continue to use.	provider intervention.
			his- 12.4%					Provider
			o-7.9%					communication ed
								used most frequently

			C = 44 ² = = = =	DVA.				and more and a discover
			Setting:	$\mathbf{DV2}$:				and reported easiest
			PCO w/ at least	Completion of				to use
			400 active	HPV vax series				
			adolescent					Feasibility:
			patients	DV3:				Multicomponent
				intervention				utilizes more
			Exclusions: Less	sustainability				resources that
			than 9 yo, not					individual
			eligible for HPV					interventions, may be
			vax					difficult to sustain
								over long period of
			Attrition: None					time
			(electronic					
			monitoring)					
Citation	Concentual	Dosign/Mathod	Somple/Sotting	Major	Magguramont	Doto Analysis	Study Findings	Decision for Use
Citation	Fromowork	Design/Method	Sample/Setting	Variables and	Wiedsurement	Data Analysis	Study Findings	Decision for Use
	FTAIllework			Variables and				
D (1		DOT	NL 242	Definitions	0	01.	DI/1	
Dempsey et al.	Inferred	RCI	N = 342	IV: 2.5 hour	Surveys	Chi-square		LOE: II
(2019). Parent	Theory of	CSS	n = 162 (CG)	provider			CG=36%	
report of	Planned		n = 180 (IG)	communication		Fishers Exact	IG=68%	Strengths:
provider HPV	Behavior	Purpose: To assess		training teaching				randomized, non-
vaccine		secondary, parent	Pt type: Parents	strong,		Descriptive	P<.001	invasive, validated
communication		reported outcomes	of young	presumptive		Statistics		data analysis tools
strategies used		of a provider	adolescents seen	techniques			DV2:	
during a		communication	at participating				CG=28%	Weaknesses: self-
randomized,		intervention aimed	PCO	DV1: Parents			IG=55%	report, potential
controlled trial		at improving		report of				recall bias, unvaried
of provider		adolescent HPV	A:	provider rec			P<.001	demographic
communication		vax	<13=59%	style				population, poor
intervention.			13-14=41%				DV3:	attrition rate
			S.	DV2: Parents			CG=45%	
Country. USA			5. f-50%	HPV vax			IG-63%	Conclusion: Giving a
Funding: CDC			m = 50%	narcantion			10-0370	strong presumptive
Funding. CDC			D.	perception			P- 003	rog improves parent
			N N					

Bias: Recall			C=77%	DV3:				attitude and
(d/t attrition			B=4%	Adolescent HPV				acceptance of HPV
rate)			O=19%	vax receipt				vax
			Setting: PCO in					
			Denver, CO.					Feasibility:
			Evolucione					low cost time
			ineligible to					effective approach
			receive HPV					encenve approach
			vay not between					
			the ages of 11-17					
			vears					
			years					
			Attrition: 53%					
			d/t invalid					
			addresses or no					
			response					
Citation	Conceptual	Design/Method	Sample/Setting	Major	Measurement	Data Analysis	Study Findings	Decision for Use
	Framework			Variables &				
				Definitions				
Dixon et al.	Theory of	RCT- cluster	N =1596	IV: HPV digital	CHICA	Chi squared test	DV:	LOE: II
(2019). An	Planned		n =1059 (CG)	educational			IG:78%	G
educational	Behavior	Purpose: Test the	n = 537 (IG)	video	Theo	t-tests	CG:52.8%	Strengths: non-
intervention to		attact of digital						
			Det D					invasive, low attrition
improve HPV		HPV vax	Pt type: Parents	DV: HPV vax		ITT	OR=3.07 with	invasive, low attrition rate, randomization
improve HPV vaccination: A		HPV vax educational	Pt type: Parents of adolescents 11	DV: HPV vax uptake		ITT	OR=3.07 with 95% CI	invasive, low attrition rate, randomization
improve HPV vaccination: A cluster		HPV vax educational intervention	Pt type: Parents of adolescents 11 to 17 yo who	DV: HPV vax uptake		ITT GEEs	OR=3.07 with 95% CI p=.003	invasive, low attrition rate, randomization Weaknesses:
improve HPV vaccination: A cluster randomized		HPV vax educational intervention delivered during a	Pt type: Parents of adolescents 11 to 17 yo who were	DV: HPV vax uptake Definitions:		ITT GEEs	OR=3.07 with 95% CI p=.003	invasive, low attrition rate, randomization Weaknesses: unblinded, clustering
improve HPV vaccination: A cluster randomized trial.		HPV vax educational intervention delivered during a clinic visit	Pt type: Parents of adolescents 11 to 17 yo who were unvaccinated or partially	DV: HPV vax uptake Definitions: Vax uptake: change in vax		ITT GEEs	OR=3.07 with 95% CI p=.003	 invasive, low attrition rate, randomization Weaknesses: unblinded, clustering in single urban health system, dichotomous
improve HPV vaccination: A cluster randomized trial. Country: USA		HPV vax educational intervention delivered during a clinic visit	Pt type: Parents of adolescents 11 to 17 yo who were unvaccinated or partially vaccinated.	DV: HPV vax uptake Definitions: Vax uptake: change in vax status as a result		ITT GEEs	OR=3.07 with 95% CI p=.003	invasive, low attrition rate, randomization Weaknesses: unblinded, clustering in single urban health system, dichotomous variable
improve HPV vaccination: A cluster randomized trial. Country: USA Funding:		HPV vax educational intervention delivered during a clinic visit	Pt type: Parents of adolescents 11 to 17 yo who were unvaccinated or partially vaccinated. A:	DV: HPV vax uptake Definitions: Vax uptake: change in vax status as a result of a clinic visit		ITT GEEs	OR=3.07 with 95% CI p=.003	invasive, low attrition rate, randomization Weaknesses: unblinded, clustering in single urban health system, dichotomous variable
improve HPV vaccination: A cluster randomized trial. Country: USA Funding: Merck-		HPV vax educational intervention delivered during a clinic visit	Pt type: Parents of adolescents 11 to 17 yo who were unvaccinated or partially vaccinated. A: 11-12 -57.4%	DV: HPV vax uptake Definitions: Vax uptake: change in vax status as a result of a clinic visit		ITT GEEs	OR=3.07 with 95% CI p=.003	 invasive, low attrition rate, randomization Weaknesses: unblinded, clustering in single urban health system, dichotomous variable Conclusion: Video

Regenstrief			15-17-17%					on risks and benefits
Program.			S:					of HPV triples the
Bias:			F-45.3%					odds of HPV vax
Sponsorship			M-54.7%					uptake
Bias			R:					
			B- 54.5%					Feasibility:
			C-8.8%					Recommended due to
			O-36.7%					ease of
								administration,
			Setting:					potential lack of
			Eskenazi					resource (tablets)
			pediatric health					
			clinics					
			Exclusions:					
			parents of					
			children who					
			were fully					
			vaccinated, not					
			able to read					
			English language					
			Attrition: None					
			(able to track vax					
			status in state					
			registry)					
Citation	Conceptual	Design/Method	Sample/Setting	Major	Measurement	Data Analysis	Study Findings	Decision for Use
	Framework			Variables and				
				Definitions				
Krantz et al.	Inferred	QI	N =105	IV: 15 minute	Online vax	Fisher's exact	DV:	LOE: V
Program. Bias: Sponsorship Bias Bias Sis Citation Conceptual Framework Design/Mether Framework Design/Mether Framework Krantz et al. Inferred QI [2017). Health Increasing HPV Increasing HPV Belief Purpose: To vaccination Model increase rate or provements				provider	registry		Preintervention-	
Increasing HPV	Belief	Purpose: To	Pt type: Medical	education w/		Clopper-Pearson	50.9%	Strengths: validated
vaccination	Model	increase rate of	providers serving	HPV facts &		exact method	Post-intervention-	analysis tools,
coverage		HPV series	adolescents	framing of rec			61.7%	completion of series

through		competition after						rather than single
provider-based		provider education	S:	DV: HPV vax			p<.05	dose
interventions.		•	f- 41%	series			-	
			m- 59%	competition				Weaknesses: no
Country: USA				rates				control group,
Funding: None			R:					minimal variability in
Bias: None			B- 74%	Definition:				demographics
			His- 1%	Series				
			O-25%	completion- receive all				Conclusions: Provider based
			Setting: PCO w/	recommended				interventions increase
			predominantly	doses				HPV series
			low income					completion rates
			patients					Feasibility: Low
								cost, limited
			Exclusion: Not					resources
			between the ages					
			of 13-17, not an					
			active patient in					
			vax registry					
			Attrition: None					
			(electronic					
			monitoring)					
Citation	Conceptual	Design/Method	Sample/Setting	Major	Measurement	Data Analysis	Study Findings	Decision for Use
	Framework			Variables and				
				Definitions				
Kumar et al.	Inferred	Descriptive-	N= 96	IV: Video w/	Questionnaire	Likert-scale	Unacceptable to	LOE: VI
(2019). A brief	Health	questionnaire	-	didactic teaching	(baseline & post-		delay:	
provider	Belief	D	Pt type:	outline HPV	test)	McNemar test	Baseline- 50%	Strengths:
training video	Model	Purpose: Assess	pediatric	disease & vax			Post- 71%	inexpensive,
Improves		efficacy &	providers				p<.01	validated IV &
comfort with		teasibility of	DI : :	DV: Provider				questionnaire
recommending		provider training	Physicians-52%	comfort w/				

the human papillomavirus vaccine. Country: USA Funding: American Academy of Pediatrics Bias: None		video about HPV vax	Residents- 6.3% NP/PA-23.9% Setting: 4 Pediatric PCOs Exclusions: Not a peds provider Attrition: 11%	counseling on HPV			Counseling for rationale: Baseline- 49% Post- 79% p<.01 Making a strong rec: Baseline- 68% Post- 84% p<.01	Weaknesses: convenience sampling, self-report, did not assess vax rates Conclusion: training video significantly improves provider comfort in counseling on vax & strong rec. Feasibility: Recommended d/t low cost, minimal resources & self- reported improvement in
Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables and Definitions	Measurement	Data Analysis	Study Findings	Decision for Use
Malo et al. (2018). Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory based investigation.	Theory of Planned Behavior	RCT CSS Purpose: To assess the impact of announcement and conversation communication training on HPV vax coverage.	N=83 n=47 (CG) n=36 (IG) Pt type: Vax prescribing clinicians serving adolescents age 11-17 years. S:	IV: 1 hr provider education course teaching the EASE approach for HPV rec DV1: provider's HPV vax attitudes	Validated pre and post training surveys	Paired t-tests Independent sample <i>t-tests</i> ANOVA	DV1: CG: M=4.4 IV: M= 4.7 p < .001 d = .62 DV2: CG: 3.5 IV: 4.1 p < .001	LOE: II Strengths: no attrition, randomization, validated measurement tools Weaknesses: short follow-up, self- report, possible social desirability

			f= 69%	DV2: subjective			<i>d</i> =.90	
Country: USA			m=31%	norms about				Conclusion: After a
Funding:				HPV vax			DV3:	1 hr HPV rec training
Grants from			Years of				CG: 4.1	course, providers
Pfizer &			practice:	DV3: self-			IG: 4 4.6	report delivering rec
National Cancer			>10 yrs: 66%	efficacy to rec				that is stronger.
Institute			5	HPV vax			p<.001	timelier, more urgent
Bias: None			Setting:				d = .89	and more consistent
			pediatric PCO	DV4: time spent				than pre-training.
			providing HPV	discussing vax			DV4:	
			vax to	8			CG: 3.8 min	Feasibility:
			adolescents				IG :3.2 min	Recommended due to
								low cost and minimal
			Exclusions:				p=.01	time commitment
			<100 11-12 yo				1	
			patients, no				d=.28	
			pediatric					
			provider to order					
			HPV vax					
			Attrition= 0%					
Citation	Conceptual	Design/Method	Sample/Setting	Major	Measurement	Data Analysis	Study Findings	Decision for Use
	Framework			Variables and				
				Definitions				
McLean et al.	Inferred	Pre- & post-test	N= 24, 658	IV: Multi-	EMR vax	GEE	DV:	LOE: III
(2017).	Theory of	(1yr post)	n =16,041 (IG)	component-	registry			
Improving	Planned	Quasi-experimental	n= 8,617 (CG)	provider			11-12 yo:	Strengths: No
human	Behavior			training,			CG pre IV: 31.9%	attrition, long FU
papillomavirus		Purpose: To	Pt type: Medical	quarterly			CG post IV:	period
vaccine use in		evaluate the	provider for	feedback of vax			44.5%	
an integrated		effectiveness of a	adolescents 11-	rates, patient				Weaknesses: multi-
health system:		multicomponent	17 уо	reminder			IG pre IV: 40.6%	component so
Impact of a		provider					IG post IV: 59.3%	increases cannot be
provider and		intervention in	A:					attributed to one item,

staff		changing HPV vax	11-12-28%	DV: Change in			p=.002	pediatric providers
intervention.		coverage	13-15-44%	HPV vax				higher in IV group
			16-17-28%	coverage			13-17yo:	
Country: USA			S:				CG pre IV: 48.4%	Conclusion: multi-
Funding: CDC			F- 49%				CG post IV:	faceted approach
Bias: None							55.4%	targeting providers
			Setting: Medical					and parents increases
			offices that serve				IG pre IV: 53%	HPV vax rates
			a large number				IG post IV: 61.7%	Feasibility:
			of adolescents in					Components such as
			regional health				p=.001	provider training low
			care system in					cost and few
			WI					resources, however
								patient recall is not
			Exclusions: Not					cost effective and
			between the ages					utilizes many
			of 11-18yo					resources
			Attrition- 0%					
			(electronically					
			followed)					
Citation	Conceptual	Design/Method	Sample/Setting	Major	Measurement	Data Analysis	Study Findings	Decision for Use
	Framework			Variables and				
				Definitions				
Perkins et al.	Inferred	RCT	N =13,118	IV: repeated	EMR	LR	Active phase:	LOE: II
(2015).	Theory of		n = 9025 (CG)	contact, focused	(pre IV, active, 6		DV:	
Effectiveness of	Planned	Purpose: Evaluate	n =4093	education on	month FU)		f:	Strengths: low
a provider	Behavior	the effectiveness of		HPV vax,			OR- 1.6	attrition rate,
focused		multi-component	Pt type:	individualized			95% CI	randomized, diverse
intervention to		provider-based	Physicians, NPs,	feedback on vax			m:	demographics
improve HPV		intervention in	PAs of	rates, incentives			OR- 11	
vaccination		increasing HPV	adolescents,				95% CI	Weaknesses: state
rates in boys		vax	adolescents 11-	DV: HPV vax				funded vax for boys,
and girls.			21yr	rates			6 month post:	

Country: USA Funding: American Cancer Society Bias: None			A: <15 yr=54% >15 yr=46% S: f=44% m=56% R: C=8% B=47% O=45% Setting: Pediatric PCO & community health center Exclusion: HPV vax completion, pregnancy Attrition: 0% (electronic tracking)	Definitions: repeated contact: HPV education at staff meeting every 6-8 weeks			f: OR-1.6 95% CI m: OR-8.5 95% CI p<.05	 limited number of practices Conclusions: multicomponent provider intervention increases HPV vax in boys & girls Feasibility: Repeated contact time consuming, many resources needed for multicomponent IV
Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables and Definitions	Measurement	Data Analysis	Study Findings	Decision for Use
Sanderson et al.	Social	Clustered,	N = 269	IV1: educational	Parent	Chi-square	IV1:	LOE: III
(2017).	Ecological	pragmatic non-	n = 167 (CG)	video/flyer &	Questionnaire		CG:32.9%	A . A
Pragmatic trial	Model	RCT	n = 194 (IG)	1 hr provider	(pre & post, 12	I'I'I'	IG: 45.4%	Strengths: non-
of an				training & rec	month FU)	L D	DD 1.00	invasive, pragmatic
intervention to		Purpose: Evaluate	Pt type: B or			LK	RR = 1.38	trial
increase human		the effectiveness of	Hisp adolescents				95% CI	
papillomavirus		provider-focused	who had					

vaccine in	and patient-focused	received no HPV	IV2: Provider	IV2:	Weaknesses: non-
safety-net	intervention	vax	training & rec		randomized, narrow
clinics.	strategies aimed at		alone	RR: 4.08	demographic range
	increasing HPV	A:		95% CI	
Country: USA	vax rates among	9-12-60%	DV: Receipt of		Conclusion: Provider
Funding: NIH	AA's and Hisp.	13-15-23%	HPV vax		recommendation had
Bias: None		16-18- 17%			4x increased HPV
		S:			vax rate, video/flyer
		f- 50%			did not. Parent report
		m- 50%			video/flyer was
		R:			helpful
		AA- 90%			
		Hisp- 10%			Feasibility:
		a			Recommended d/t
		Setting: PCO for			low cost and non-
		low income			invasive
		Exclusions: not			
		AA or Hisp, not			
		adolescent,			
		received HPV			
		vax			
		Attrition: 27%			
		(IG) 38% (CG)			
		d/t refusal			
		a, . 1010.001			

Appendix B

Table 2

Synthesis Table

	Brewer	Dempsey	Dempsey	Dixon	Krantz	Kumar	Malo	McLean	Perkins	Sanderson
Year	2017	2019	2019	2019	2017	2019	2018	2017	2015	2017
Design	RCT	RCT/CSS	RCT/CSS	RCT	QI	DS	RCT/CSS	QE	RCT	NRCT
LOE	II	II	II	II	V	VI	II	III	II	III
			St	udy Characte	eristics					
Demographics										
Age Range (yo)	11-17	9-18	9-14	11-17	13-17		11-17	11-17	11-21	9-18y
Female %		50.3	50	45.3	41		69	49	44	50
Caucasian %		54.9	77	8.8	25				8	0
Setting										
USA	Х	X	Х	Х	Х	Х	Х	Х	Х	Х
PCO	Х	X	Х	Х	Х	Х	Х	Х	Х	Х
Sample	30(clinics)	43,132	342	1596	105	96	83	24, 658	13,118	269
Measurement Tools										
EMR	Х	Х							Х	
Registry		Х		X	Х			Х		
Survey		Х	Х			Х	X			Х
				Interventio	ns					
Provider Training (SIV)	Х		Х		Х	Х	Х			
Provider Training (MIV)		Х						Х	Х	
Parent Education				Х						
Parent & Provider Education										Х
				Outcome	S					
Change in HPV vax rates	1	1	1	1	1			1	1	1
Provider Perception			_			1	1			
Parent Perception			1							

Key: CSS= Cross Sectional Survey, DS= Descriptive Survey, EMR= Electronic Medical Record, LOE= Level of Evidence, MIV= Multicomponent Intervention, NRRCT= Non-randomized controlled trial, PCO= Primary Care Office, QE= Quasi-experimental, QI= Quality Improvement, RCT= Randomized Controlled Trial, SIV= Single Intervention, \uparrow = significantly increased

Appendix C

Figure 1

The Health Belief Model

The Health Belief Model



Appendix D

Figure 2

Rosswurm & Larrabee's Model for EBP Change



Appendix E

Table 3

Budget Plan

Phase	Activities	Cost	subtotal	Total
Educational Class	Design and print educational handouts (15 total x \$.10/page)	\$1.50		
	Laptop to stream educational app*	\$0		
	Educational app	\$0		
	HDMI cable to connect laptop to television	\$10		
	Television to project images larger*	\$0		
	Design and print pre and post intervention surveys (30 total x \$.10/page)	\$3.00		
	Meeting room space for 1 hour*	\$0		
	Electricity and air conditioning in meeting space*	\$50		
	Pay 15 providers for 1 hour of their time (\$65/hr)*	\$0		
	Lunch for 15 people	\$200	\$264.50	
Data	Intellectus	\$75		
Collection	3 month post intervention surveys (15x \$.10 each)	\$1.50	\$75.50	\$340.00